Drug Discovery
ByHow Will Emerging Drug Pricing Policies Reshape the Global Biopharma Industry in the Near and Long Term?
The global biopharmaceutical industry is entering a new policy-driven era as governments intensify efforts to control drug costs,…
Strategic Industry Release: How AI Companies Led Biopharma Innovation Through Major Collaborations in 2025
Artificial intelligence companies emerged as critical innovation partners for the global biopharmaceutical industry in 2025, reshaping how drugs…
What broader implications does Zealand Pharma’s petrelintide trial setback raise for the GLP-1 obesity market?
Trial Context Recap ZUPREME-1 delivered 10.7% peak weight loss over 42 weeks across 493 patients, surpassing placebo but…
The $10B+ Pharma Titans of 2025: Fortress Builders or House of Cards?
In 2025, only nine pharmaceutical brands crossed the $10 billion revenue threshold, collectively generating $125B+ while representing 25% of global pharma sales—yet their…
Can Eli Lilly and Company’s “Triple-G” AI-Enabled Next-Gen Drug Deliver 15%+ Weight Loss and Redefine the $100B Obesity-Diabetes Market Dominated by Novo Nordisk A/S?
Key Highlights: AI-Driven Clinical Design Unlocks Superior Metabolic OutcomesEli Lilly and Company’s late-stage trial results for retatrutide highlight…
Can Novartis AG’s $3 Billion AI-Driven Oncology Bet Redefine Precision Breast Cancer Treatment and Accelerate Next-Gen Drug Discovery?
Key Highlights: AI-Led Drug Discovery Accelerates Target Identification and ValidationNovartis AG’s acquisition of SNV4818 from Synnovation Therapeutics, Inc.…
